Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
Drug Product Stability01:16

Drug Product Stability

The long-term stability of drug products is critical to ensuring their quality, safety, and effectiveness over time. Stability directly influences a product's ability to maintain its intended characteristics, ensuring it performs as expected during its intended shelf life. Key attributes such as drug potency, impurities, dissolution, and other physicochemical measures of performance are tested to assess stability. These parameters indicate how well the product retains its quality over time and...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
Automated Microbial Diagnostics01:24

Automated Microbial Diagnostics

Automated diagnostic analyzers have transformed clinical microbiology by providing rapid and reliable methods for pathogen identification and antibiotic susceptibility testing. Among these systems, the Vitek 2 is widely used because it automates the traditionally labor-intensive processes of microbial identification (ID) and antibiotic susceptibility testing (AST), delivering standardized and timely results that are essential for effective patient care.Microbial Identification with ID CardsThe...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to Letter to the Editor: "Efficacy and Safety of Combination Therapy With Low Dose of Telmisartan and S-Amlodipine in Patients With Hypertension: A Randomized, Double-Blind, Multicenter, Therapeutic Confirmatory, Phase III Clinical Trial".

Clinical therapeutics·2026
Same author

Efficacy and Safety of Fimasartan/Indapamide Combination Therapy versus Fimasartan Monotherapy in Patients with Essential Hypertension Inadequately Responding to Fimasartan 30 mg (FINEDUO): A Randomized, Double-Blind, Multicenter, Phase III Study.

Drug design, development and therapy·2026
Same author

Low-Dose Telmisartan/Amlodipine in Essential Hypertension: A Phase III Trial.

Journal of clinical hypertension (Greenwich, Conn.)·2026
Same author

Asian expert consensus on high-quality hypertension management.

Hypertension research : official journal of the Japanese Society of Hypertension·2026
Same author

Gastrointestinal Stromal Tumor: History, Molecular Subtypes, and Risk Stratification.

Journal of gastric cancer·2026
Same author

Predictive Value of Insertion/Deletion Rate in Patients With Gastric Cancer Treated With Nivolumab Plus Chemotherapy.

Journal of gastric cancer·2026
Same journal

Conformational dynamics of pneumococcal polysaccharide conjugates drive UV-vis quantification errors and a strategy to enable UV-vis spectrophotometer quantification.

Biologicals : journal of the International Association of Biological Standardization·2026
Same journal

Refining the regulatory and ethics context of controlled human infection models - a stakeholder meeting report.

Biologicals : journal of the International Association of Biological Standardization·2026
Same journal

Longevity of humoral response in recipients of rabies pre-exposure prophylactic vaccination with Abhayrab®.

Biologicals : journal of the International Association of Biological Standardization·2026
Same journal

Collaborative studies to establish WHO International Reference Reagents for diphtheria and tetanus antitoxin for use in the flocculation test.

Biologicals : journal of the International Association of Biological Standardization·2026
Same journal

Alternative approaches to phase III clinical trials for vaccine efficacy and licensure: the role of real-world evidence - a meeting report.

Biologicals : journal of the International Association of Biological Standardization·2026
Same journal

Leveraging analytical and bioprocess platforms for biological product development and commercialization - A meeting report.

Biologicals : journal of the International Association of Biological Standardization·2026
See all related articles

Related Experiment Video

Updated: Jun 20, 2026

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis
06:26

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis

Published on: July 28, 2023

Model format for a vaccine stability report and software solutions.

Jinho Shin1, James Southern, Timothy Schofield

  • 1Department of Immunization, Vaccines and Biologicals, World Health Organization, CH-1211 Geneva 27, Switzerland. shinj@who.int

Biologicals : Journal of the International Association of Biological Standardization
|September 2, 2009
PubMed
Summary
This summary is machine-generated.

Developing a standardized vaccine stability report format and software is crucial for regulatory compliance and efficient data management. This approach ensures consistency while allowing for company-specific flexibility.

More Related Videos

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development
12:53

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

Published on: March 16, 2022

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus (MRSA) Infection
07:32

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus (MRSA) Infection

Published on: September 1, 2023

Related Experiment Videos

Last Updated: Jun 20, 2026

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis
06:26

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis

Published on: July 28, 2023

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development
12:53

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

Published on: March 16, 2022

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus (MRSA) Infection
07:32

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus (MRSA) Infection

Published on: September 1, 2023

Area of Science:

  • Vaccinology
  • Pharmaceutical Sciences
  • Regulatory Affairs

Background:

  • The International Association for Biologicals Workshop focused on vaccine stability evaluation throughout its lifecycle.
  • Current practices lack a standardized format for vaccine stability reports, leading to potential inconsistencies.

Purpose of the Study:

  • To discuss and propose a model format for vaccine stability reports.
  • To explore software solutions for managing vaccine stability data.

Main Methods:

  • Presentations at the workshop highlighted the benefits of a model report format.
  • Discussions emphasized the need for flexibility to accommodate diverse industry practices.

Main Results:

  • A model format aligning with regulatory requirements and the ICH common technical document was proposed.
  • Software solutions should prioritize ease of use and prevent errors in stability design and data interpretation.

Conclusions:

  • Adoption of a model format requires agreement on content between industry and regulators.
  • User-friendly software with robust error-checking is essential for effective vaccine stability management.